Literature DB >> 837375

Evidence for carrier-mediated transport of melphalan by L5178Y lymphoblasts in vitro.

G J Goldenberg, M Lee, H Y Lam, A Begleiter.   

Abstract

Mechanism of transport of the alkylating agent [14C]melphalan was investigated in L5178Y lymphoblasts in vitro. A time course of melphalan uptake was approximately linear for 5 to 10 min and thereafter entered a plateau region. Evidence that unidirectional influx of melphalan is carrier mediated was that uptake obeyed simple Michaelis-Menten kinetics, that it demonstrated chemical specificity, and that the cell/medium distribution ratio of drug decreased with increasing extracellular drug concentration. The kinetic parameters for melphalan transport consisted of a Km (mean +/- S.E.) of 1.53 +/- 0.18 X 10(-4) M and a transport capacity (Vmax) of 3.48 +/- 0.31 X 10(-17) mole/min/cell. Findings suggesting that transport was at least in part energy dependent and not simply a passive process were that drug uptake was temperature sensitive and sodium dependent. Analysis of cell sap constituents indicated the presence of intact drug within the cell. The percentage of radioactivity (mean +/- S.D.) found in the cell sap fraction was 95.8 +/- 2.2% of total cell activity, and 92.6 +/- 4.1% of this was trichloroacetic acid soluble. Thin-layer chromatography of the cell sap fraction and medium each revealed that the majority of radioactivity migrated as a single peak with an RF value identical with that obtained for free drug. The alkylating potential of intact drug complicated interpretation of the finding of apparent uphill transport against a concentration gradient. This observation, together with the relatively low cell-medium ratio (mean +/- S.D.) of 3.07 +/- 1.07, favors the concept that melphalan transport occurs by a facilitated diffusion process, although an active transport system has not been entirely excluded. The relative insensitivity of melphalan uptake to a wide range of metabolic inhibitors also suggests that transport is by a facilitated diffusion mechanism rather than an active process. Other alkylating agents and several amino acids including the L and D isomers of phenylalanine did not inhibit melphalan transport; thus a native substrate was not identified for the melphalan carrier and transport was by a mechanism separate from that of other alkylating agents.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 837375

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Effects of amino acids on the transport and cytotoxicity of melphalan by human bone marrow cells and human tumor cells.

Authors:  M Dufour; L C Panasci; J St Germain; L Boulet
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

2.  Effect of administration of sodium cyanate and melphalan on the lifespan of P388 tumor-bearing CD2F1 mice.

Authors:  M Dufour; J St Germain; V Skalski; A Dorato; P Lazarus; L C Panasci
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

3.  The effect of dietary amino acids on the gastrointestinal absorption of melphalan and chlorambucil.

Authors:  C G Adair; J C McElnay
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Increased cancericidal activity of PTT.119; a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. II. In vivo bioassay.

Authors:  M J Yagi; M Zanjani; J F Holland; J G Bekesi
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Studies on the mechanism of gastrointestinal absorption of melphalan and chlorambucil.

Authors:  C G Adair; J C McElnay
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow.

Authors:  B A Robinson; R D Clutterbuck; J L Millar; T J McElwain
Journal:  Br J Cancer       Date:  1985-12       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.